Erlotinib-induced acute hepatitis in a patient with pancreatic cancer

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 3, 2008, Pages 191-199

  Saif, Muhammad Wasif ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; ERLOTINIB; GEMCITABINE; OXALIPLATIN; PREGABALIN;

ACUTE HEPATITIS; ADULT; ADVANCED CANCER; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; JAUNDICE; LIVER FUNCTION TEST; MALE; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; SIDE EFFECT;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CYTOCHROME P-450 ENZYME SYSTEM; DEOXYCYTIDINE; HEPATITIS, TOXIC; HUMANS; LIVER; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 42049086972     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
3. Saif MW. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006. JOP. 2006;7:337-348.
4. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Saletti P, Bajetta E, et al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol. 2005;23(16S):LBA4010.
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
7. Hidalgo M, Siu LL, Nemunitis J, et al. Phase I and pharmarologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
8. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer. 2004;6:S20-3.
9. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Sin LL. Multi-center phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85.
10. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-5899.
11. Tarceva package insert. Available online: http://www.gene.com/gene/ products/information/oncology/tarceva/insert.jsp. Accessed April 19, 2007.
12. Ramanarayanan J, Scarpace SL. Acute drug induced hepatitis due to erlotinib. JOP. 2007;8:39-43.
13. Saif MW. Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007. JOP. 2007;8:166-176.
14. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10:461-466.
15. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buehler M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992;90:1352-1360.
16. Yamanaka Y, Friess H, Kobrin MS, Buehler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13:565-569.
17. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23: 6657-6663.
18. Durkin AJ, Bloomston PM, Rosemurgy AS, et al. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg. 2003;186:431-436.
19. Dragovich T, Huberman M, Von Hoff DD, et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol. 2006;60:295-303.
20. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006; 24:3069-3074.
21. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000;18:2780-2787.
22. Ho C, Davis J, Anderson F, Bebb G, Murray N. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol. 2005;23:8531-8533.
23. Carlini P, Papaldo F, Fabi A, et al. Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol. 2006;24:e60-61.